Biological
Hiberix clinical trials
Also written Hiberix.
- studies test it
- 7
- open now
- 0
- in phase 3
- 5
- first study started
- 2005
How studies write it
Studies that test it under each name
Brand
Combined with it in one product
Studies by the year they started
7 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 2
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Diphtheria-Tetanus-Pertussis Vaccine (3) · Hepatitis B Vaccines (3) · Pediarix (2) · Diphtheria-Tetanus-acellular Pertussis Vaccines (2) · 13-valent pneumococcal vaccine (1) · PHiD-CV vaccine (1) · Poliovirus Vaccine, Oral (1) · MVAC Regimen (1)
Studies
Open first, then newest update. How each study uses Hiberix is read from its arms, and is right about nine times in ten.
Testing it · 7
- This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized VaccineCompletedPhase 3GlaxoSmithKlineNCT03207750Written as Hiberix
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of AgeCompletedPhase 3GlaxoSmithKlineNCT00814710Written as Tritanrix-HepB/Hib
- Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & InfantsCompletedPhase 2GlaxoSmithKlineNCT01262872Written as Tritanrix™-HepB/Hib
- Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy InfantsCompletedPhase 3GlaxoSmithKlineNCT01000974Written as GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)
- Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in InfantsCompletedPhase 3GlaxoSmithKlineNCT00169442Written as Tritanrix™-HepB/Hiberix™
- Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.CompletedPhase 3GlaxoSmithKlineNCT00412854Written as Hiberix
- B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy InfantsCompletedPhase 2Novartis VaccinesNCT00488683Written as Hib
Given in every arm · 16 — Hiberix is usual care beside what is tested
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy InfantsCompletedPhase 3GlaxoSmithKlineNCT03621670Written as Hiberix
- Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood VaccinesCompletedPhase 4Duke UniversityNCT03530124Written as Hib
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)CompletedPhase 3Merck Sharp & Dohme LLCNCT03893448Written as HIBERIX™
- A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)CompletedPhase 3Merck Sharp & Dohme LLCNCT03620162Written as HIBERIX™
- Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy InfantsCompletedPhase 3GlaxoSmithKlineNCT02096263Written as Hiberix
- Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850ACompletedPhase 3GlaxoSmithKlineNCT01175083Written as Tritanrix-HepB/Hib
- Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same VaccinesCompletedPhase 3GlaxoSmithKlineNCT00547248Written as Hiberix
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate VaccineCompletedPhase 3GlaxoSmithKlineNCT00344318Written as Hiberix
- Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same VaccineCompletedPhase 3GlaxoSmithKlineNCT00911144Written as GSK Biologicals' Hiberix™
- Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.CompletedPhase 3GlaxoSmithKlineNCT00829010Written as Tritanrix-HepB/Hib
- A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy InfantsCompletedPhase 3GlaxoSmithKlineNCT02447432Written as DTPw-HBV/Hib
- Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™CompletedPhase 3GlaxoSmithKlineNCT00680914Written as GSK Biologicals' Hiberix™
- Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in ChildrenCompletedPhase 3GlaxoSmithKlineNCT00696423Written as Hiberix™
- Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 StudyCompletedPhase 3GlaxoSmithKlineNCT00291343Written as Hiberix™
- Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed SubjectsCompletedPhase 3GlaxoSmithKlineNCT00317109Written as Hiberix™
- A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In InfantsCompletedPhase 3Novartis VaccinesNCT00474526Written as Hib
As the comparator · 9 — what is tested is compared with Hiberix
- A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young ChildrenCompletedPhase 3PfizerNCT03574389Written as Hib
- Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib VaccineCompletedPhase 3GlaxoSmithKlineNCT01309646Written as Hiberix™
- Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.CompletedPhase 3GlaxoSmithKlineNCT00326118Written as Hiberix™
- Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered SeparatelyCompletedPhase 3GlaxoSmithKlineNCT01457508Written as Hib (Hiberix™)
- Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 VaccineCompletedPhase 2GlaxoSmithKlineNCT00323622Written as Hiberix®
- Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™CompletedPhase 2GlaxoSmithKlineNCT01061541Written as Hiberix™
- Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in ChildrenCompletedPhase 2Sanofi Pasteur, a Sanofi CompanyNCT00771849Written as Haemophilus Influenzae Type b (Hib) vaccine
- Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.CompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT00313911Written as Tritanrix-HepB/Hib
- Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™CompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT00534833Written as Tritanrix-HepB/Hib™
Codes
What other systems call Hiberix · ClinicalTrials.gg INT004990
- MeSH (NLM) C514867HiberixOne source NLM
- UNII (FDA) C9R35M8XV6HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGENConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C514867 | Hiberix | One source NLM |
| UNII (FDA) | C9R35M8XV6 | HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.